濮阳东方医院男科收费怎么样濮阳东方医院男科坐公交路线,濮阳东方医院看男科病技术非常哇塞,濮阳东方妇科怎么预约,濮阳东方医院男科割包皮收费低,濮阳东方医院男科割包皮价格透明,濮阳东方医院男科治疗早泄价格,濮阳东方看男科病专业吗

SAN FRANCISCO, Aug. 23 (Xinhua) -- The amount of malware targeted at devices based on Google's Android platform surged 76 percent in the second quarter over the previous three months in 2011, making it the most attacked mobile operating system, computer security firm McAfee said on Tuesday.A new McAfee study found that in the second quarter, Android- based malware surpassed Nokia's Symbian as the most popular target for mobile malware developers.While Symbian and Java ME, a platform designed for mobile devices and other embedded systems, remain the most targeted to date, the rapid rise in Android malware indicates that the platform could become an increasing target for cyber criminals McAfee said.Models pose with the new Samsung Galaxy S Android smartphone during its launch ceremony at the headquarters of Samsung Electronics in Seoul in this June 8, 2010 file photograph.It warned that the attacks on Android platform could affect everything from calendar apps, to text messages, and even a fake Angry Birds updates.According to the study, malware on mobile platforms is increasing steadily, often mimicking the same code as personal computer-based threats, as vast amount of personal and business data are now found on user's smartphones and other mobile devices."This year we've seen record-breaking numbers of malware, especially on mobile devices, where the uptick is in direct correlation to popularity," Vincent Weafer, senior vice president of McAfee Labs, said in a statement."Overall attacks are becoming more stealth and more sophisticated, suggesting that we could see attacks that remain unnoticed for longer periods of time," he noted.

WASHINGTON, June 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday unveiled in a report a new strategy to meet the challenges posed by rapidly rising imports of FDA- regulated products and a complex global supply chain.The report, titled "Pathway to Global Product Safety and Quality," calls on the agency to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers.According to the report, the FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality. The coalitions of regulators will develop international data information systems and networks, and increase the regular and proactive sharing of data and regulatory resources across world markets.The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and information technology. It increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk."FDA regulated imports have quadrupled since 2000. The FDA and our global regulatory partners recognize this new reality and realize we must work proactively and collaboratively to address the challenges we face," FDA Commissioner Margaret Hamburg said in a statement. "The FDA must further collaborate and leverage in order to close the gap between our import levels and our regulatory resources. This report is an important step in ensuring we are able to fulfill our critical public health mission."

WASHINGTON, June 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday unveiled in a report a new strategy to meet the challenges posed by rapidly rising imports of FDA- regulated products and a complex global supply chain.The report, titled "Pathway to Global Product Safety and Quality," calls on the agency to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers.According to the report, the FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality. The coalitions of regulators will develop international data information systems and networks, and increase the regular and proactive sharing of data and regulatory resources across world markets.The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and information technology. It increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk."FDA regulated imports have quadrupled since 2000. The FDA and our global regulatory partners recognize this new reality and realize we must work proactively and collaboratively to address the challenges we face," FDA Commissioner Margaret Hamburg said in a statement. "The FDA must further collaborate and leverage in order to close the gap between our import levels and our regulatory resources. This report is an important step in ensuring we are able to fulfill our critical public health mission."

SYDNEY, Aug. 2 (Xinhua) -- Australia's general practitioners ( GPs) will not back the idea of routine prostate cancer tests for men as young as 40 despite growing calls for regular screening, the nation's largest professional general practice organization said on Tuesday.Spokesman for the Royal Australian College of General Practitioners (RACGP), Professor Chris Del Mar said there was not enough solid evidence to suggest major benefits from routine screening and that current tests were unable to detect "nasty" and potentially deadly forms of prostate cancer from ones that will not cause any harm."The problem is you end up treating lots of people who don't need to be treated," Del Mar said, adding that treatment could leave men impotent and with incontinence problems."You will treat 20 times as many people than would have ever been bothered by it. We don't yet know that treating prostate cancer is better than not treating it. We are not sure it does any good and could be doing more harm," he said.On the other hand, Australia's urologists and pathologists both want men aged 40 and over who are worried about developing the disease to be offered tests.The Royal College of Pathologists (RCPA) on Tuesday released an official recommendation on routine screening for men aged 40 and over if they were concerned about prostate cancer.The pathologists argue that blood tests for prostate cancer in men under 50 can predict their future risk of developing the disease by measuring their prostate specific antigen levels (PSA).They say that men with high PSA levels for their age should be tested annually, while those PSA levels are below the average could be tested less frequently.Their call for more routine testing contrasts with recommendations for GPs, whose `Red Book' medical guide does not support regular screening.Instead, it suggests GPs should inform men aged 50-70 of the risks and benefits of screening and only test if the patient requests one.RACGP spokesman Del Mar, who co-wrote the RACGP's recommendations, said while the Red Book was being revised "we are not going to liberalize it".Prostate cancer is one of the most common forms of cancer in Australia.About 20,000 cases of prostate cancer are diagnosed each year, with 3,300 men dying.Given the debate around prostate cancer tests, the Royal College of Pathologists wants to work with GPs, urologists and other medical organizations to develop a consensus on how and when to test for the disease, in a similar way to how experts approach breast cancer."It would be a good outcome for prostate cancer if we worked towards developing more of an umbrella document which reflected consensus among different stakeholder organizations. ," RCPA President Paul McKenzie said.